Have a Question? Call Us: (805) 497-8258
This medication requires a prescription from your doctor.
5mg capsule / 0.03% solution
or 600mg powder for reconstitution
Atomized intranasal amphotericin is the antifungal of choice to significantly reduce fungi and mycotoxins associated with biotoxin illness. Amphotericin B is a powerful antifungal that binds to the fungal cell membrane, thereby causing membrane leakage and cell death. This medication is recommended as part of the Brewer Protocol and Dr. Neil Nathan’s protocols. It is an essential part of multiple treatment protocols for mold illness and resistant nasal infections.
Topical Sinus Therapy Methods
Medicated Sinus Rinse Therapy – This method flushes the nasal cavities with a medicated saline solution. The medication is mixed with a saline solution and a nasal rinse bottle is used to irrigate the nasal passages and sinuses.
Atomized Treatment – This method uses an atomizer to pump in liquid medication to the sinus area with an easy-to-use motorized device. The compact electronic atomizer releases the liquid medication into a mist that gets inhaled into the nasal passages and sinus cavities.
Amphotericin and EDTA
Atomized intranasal EDTA is often used first to work against the biofilm coating clearing the way for a direct attack by the amphotericin. Once the biofilm is disrupted aerosolized intranasal amphotericin B is used to begin to clear the nasal colonized fungi and mycotoxins.
Dosing
There are a variety of options for prescribing amphotericin for intranasal and oral use.
- 5mg amphotericin capsule mixed with 15ml of saline results in a 0.03% solution.
- 600mg powder for reconstitution makes 0.06% solution that can be used intranasally and taken orally.
Research
- Chronic Illness Associated with Mold and Mycotoxins: Is Naso-Sinus Fungal Biofilm the Culprit? – Joseph H. Brewer, Jack D. Thrasher, and Dennis Hooper in Toxins (PubMed)
- Diagnosis and treatment of chronic rhinosinusitis: focus on intranasal Amphotericin B – Therapeutics and Clinical Risk Management (PMC)
- Intranasal antifungal treatment in 51 patients with chronic rhinosinusitis. – Journal of Allergy and Clinical Immunology (PubMed)
- Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebo-controlled, double-blind pilot trial. – Journal of Allergy and Clinical Immunology (PubMed)